News

Financial support call for startups active in urban mobility

Published on | 1 month ago

Programmes
Climate, Energy, Mobility EIT

EIT Urban Mobility has opened a call for applications aimed at startups addressing urban mobility challenges. Eligible companies can apply for funding of up to €2.5 million. 

The initiative seeks to enhance Europe’s innovation capacity in urban mobility by supporting pre-seed, seed, and Series A startups. Financial aid is intended to bolster the growth of innovative solutions targeting for example congestion, carbon emissions, urban logistics, share mobility and accessibility in urban areas.

To be considered eligible for this Call, applicants must also meet all the following mandatory criteria:

  • You are a startup currently engaged in an active fundraising round (pre-seed/seed or series A round).
  • Your proposed innovations target the Urban Mobility market.
  • You may not apply to three consecutive cut-offs. After submitting an application to two consecutive cut-offs, you must skip at least the following cut-off before applying again.
  • You are not currently part of EIT Urban Mobility equity portfolio.
  • Your company pre-money valuation does not exceed €50,000,000.
  • Your startup has individual founders or executive team members who jointly hold more than 40% share of the company’s equity before the current fund raising.
  • You have a prototype, pilot, or Minimum Viable Product (MVP).

Funding is provided through an open application process with multiple cut offs throughout 2026: 

  • 1st cut-off date: 23 February 2026
  • 2nd cut-off date: 18 May 2026
  • 3rd cut-off date: 31 August 2026
  • 4th cut-off date: 16 November 2026

Interested startups can find all the details regarding the application procedure on the website of the call. 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1824 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.